Physician profile
Stephen A Dada
NPI 1710040605
$3,213.64
in general payments reported to CMS, 2019-2025
31 companies · $49.79 in 2025
The $49.79 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $136 · 2021: $507 · 2022: $1,009 · 2023: $549 · 2024: $465 · 2025: $49.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $968.31 | 2021-2023 | Rinvoq, Dalvance, Avycaz |
| Intuitive Surgical, INC. | $215.45 | 2019-2024 | Da Vinci Surgical System |
| Integra Lifesciences Corporation | $162.89 | 2023-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Ethicon US, LLC | $144.52 | 2019-2023 | Enseal, Echelon; Endopath, Evarrest |
| Lexington Medical, INC. | $142.06 | 2021 | |
| Biotissue Holdings INC. | $136.23 | 2024 | |
| Medtronic, INC. | $135.54 | 2021-2024 | Signia |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2024 | Andexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.45 | 2021-2023 | Xifaxan, Trulance |
| Angiodynamics, INC. | $105.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.77 | 2021-2023 | Entyvio |
| Janssen Biotech, INC. | $78.49 | 2021-2023 | Simponi Aria, Simponi, Stelara |
| Kci USA, INC. | $76.48 | 2022 | |
| Covidien LP | $60.67 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $59.85 | 2022-2023 | |
| Acell, INC. | $56.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.89 | 2022-2023 | Dupixent |
| Zimmer Biomet Holdings, INC. | $46.16 | 2020 | |
| Shionogi INC | $44.71 | 2024-2025 | Fetroja |
| Qol Medical, LLC | $38.10 | 2022 | |
| Intercept Pharmaceuticals, INC. | $36.33 | 2022 | |
| Olympus America INC. | $32.50 | 2019-2020 | |
| Gilead Sciences, INC. | $29.89 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.06 | 2021 | |
| Endologix LLC | $22.94 | 2025 | Endocross Device, Torus Stent Graft System |
| Ferring Pharmaceuticals INC. | $22.03 | 2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $21.29 | 2022 | |
| Allergan, INC. | $21.13 | 2019 | |
| Alfasigma USA, INC. | $20.12 | 2021 | |
| Redhill Biopharma INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.